Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Mandel Sher"'
Autor:
Lorcan McGarvey, Jaclyn A. Smith, Alyn Morice, Surinder S. Birring, Kian Fan Chung, Peter V. Dicpinigaitis, Akio Niimi, Michael S. Benninger, Mandel Sher, Yuko Matsunaga, Sayaka Miyazaki, Mitsuaki Machida, Hiroyuki Ishihara, Adnan Mahmood, Juan-Carlos Gomez
Publikováno v:
McGarvey, L, Smith, J A, Morice, A, Birring, S S, Chung, K F, Dicpinigaitis, P V, Niimi, A, Benninger, M S, Sher, M, Matsunaga, Y, Miyazaki, S, Machida, M, Ishihara, H, Mahmood, A & Gomez, J-C 2022, ' A randomized, double-blind, placebo-controlled, parallel-group phase 2b trial of p2x3 receptor antagonist sivopixant for refractory or unexplained chronic cough ', Lung . https://doi.org/10.1007/s00408-022-00592-5
Introduction To determine the optimal dose of sivopixant, a highly selective P2X3 receptor antagonist, for refractory or unexplained chronic cough (RCC/UCC). Methods In this phase 2b, randomized, double-blind, placebo-controlled, parallel-group, mult
Autor:
Mandel Sher, Jaclyn Smith, Michael Blaiss, Alan Goldsobel, Ronghua Yang, Margaret Garin, Catherine Bonuccelli
Publikováno v:
Journal of Allergy and Clinical Immunology. 151:AB162
Autor:
Alan Goldsobel, Michael Blaiss, Mandel Sher, Surinder Birring, Jaclyn Smith, Laurent Harvey, Ronghua Yang, Catherine Bonuccelli, Margaret Garin
Publikováno v:
Journal of Allergy and Clinical Immunology. 151:AB161
Autor:
Mandel Sher, Jacqueline D. Squire
Publikováno v:
Immunology and Allergy Clinics of North America. 40:471-483
The number of disorders associated with congenital or acquired asplenia and functional hyposplenism has increased substantially over the past couple decades. Previously, screening for asplenia and hyposplenism was a barrier to identifying patients at
Autor:
Christina Ciaccio, Alan B. Goldsobel, Aikaterini Anagnostou, Kirsten Beyer, Thomas B. Casale, Antoine Deschildre, Montserrat Fernández-Rivas, Jonathan O'B. Hourihane, Marta Krawiec, Jay Lieberman, Amy M. Scurlock, Brian P. Vickery, Alex Smith, Stephen A. Tilles, Daniel C. Adelman, Kari R. Brown, Amal H. Assa'ad, David I. Bernstein, J. Andrew Bird, Tara F. Carr, Warner W. Carr, Amarjit S. Cheema, Jonathan Corren, Amy Liebl Darter, Morna J. Dorsey, Stanley M. Fineman, David M. Fleischer, Stephen B. Fritz, Shaila U. Gogate, Alexander N. Greiner, Frank C. Hampel, Joshua S. Jacobs, Sanjeev Jain, Kirsi Jarvinen-Seppo, David K. Jeong, Douglas T. Johnston, Rita Kachru, Edwin H. Kim, Majed Koleilat, Bruce J. Lanser, Stephanie A. Leonard, Mary C. Maier, Michael E. Manning, Lyndon E. Mansfield, Jonathan Matz, Kari Nadeau, Jason A. Ohayon, Elena Perez, Daniel H. Petroni, Stephen J. Pollard, Punita Ponda, Jay M. Portnoy, Rima Rachid, Paul H. Ratner, Rachel Robison, Ned T. Rupp, Georgiana M. Sanders, Hemant P. Sharma, Ellen R. Sher, Lawrence D. Sher, Mandel Sher, Wayne G. Shreffler, Dareen D. Siri, Helen S. Skolnick, Weily Soong, Daniel F. Soteres, Jonathan M. Spergel, Allan Stillerman, Gordon L. Sussman, Jonathan Tam, Pooja Varshney, Susan Waserman, Hugh H. Windom, Robert Wood, William H. Yang
Publikováno v:
Annals of Allergy, Asthma & Immunology. 129:758-768.e4
Autor:
Laurent Harvey, Mandel Sher, James H. Hull, Sylvain Lanouette, Surinder S. Birring, Catherine M. Bonuccelli, Alyn H. Morice, Alan B. Goldsobel, Jaclyn A. Smith, Ella Li
Publikováno v:
Airway pharmacology and treatment.
Autor:
Peter V. Dicpinigaitis, Jaclyn A. Smith, Melanie Wosnitza, Lorcan McGarvey, Alyn H. Morice, Laurent Guilleminault, Mandel Sher, Riitta Saarinen, Philippe Vieira Pires, Akio Niimi, Katrin Roth, Michael Vaezi
Publikováno v:
Airway pharmacology and treatment.
Autor:
Jacqueline D, Squire, Mandel, Sher
Publikováno v:
Immunology and allergy clinics of North America. 40(3)
The number of disorders associated with congenital or acquired asplenia and functional hyposplenism has increased substantially over the past couple decades. Previously, screening for asplenia and hyposplenism was a barrier to identifying patients at
Autor:
Lorcan P McGarvey, Zhi Jin Xu, Vivek Iyer, James Krainson, James H. Hull, Mark H Gotfried, Jaclyn A Smith, David Muccino, Gary C Steven, Douglas McQuaid, David I. Bernstein, Gregory Daniel Brooks, David Elkayam, Wen-Chi Wu, Selwyn Spangenthal, Mandel R Sher, Jaclyn A. Smith, Yu-Ping Li, John J Condemi, Ellen R Sher, John R Holcomb, W. Carr, Gary N Gross, SM Parker, Gary D Berman, Ratko Djukanovic, Thomas B. Casale, Jason H Friesen, Krishna Sundar, Christopher E. Brightling, Michael Denenberg, Neil Ettinger, S S Birring, Faisal Alfonso Fakih, Bruce M Prenner, Lorcan McGarvey, Niran J Amar, Jonathan Corren, Tim Harrison, Shaila U Gogate, William W. Storms, Alyn H. Morice, Iftikhar Hussain, Leon S Greos, Anthony Montanaro, Anthony P. Ford, James S Good, Eric J Schenkel, Surinder S. Birring, Thomas R Murphy, Michael S Kaplan, William R Lumry, Jonathan Matz, Michael M. Kitt, Mandel Sher, Alan B Goldsobel, Ian D. Pavord
Publikováno v:
Protocol 012 Investigators 2020, ' Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial ', The Lancet Respiratory Medicine . https://doi.org/10.1016/S2213-2600(19)30471-0
BACKGROUND: Gefapixant is a P2X3 receptor antagonist that has shown promise for the treatment of refractory and unexplained chronic cough. The aim of this study was to evaluate the efficacy of gefapixant compared with placebo after 12 weeks of treatm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bed8062bd34a8ad548083ad97ee59fbd
https://pure.qub.ac.uk/en/publications/gefapixant-a-p2x3-receptor-antagonist-for-the-treatment-of-refractory-or-unexplained-chronic-cough-a-randomised-doubleblind-controlled-parallelgroup-phase-2b-trial(5aa94b05-a819-433a-a265-b0ce6c143476).html
https://pure.qub.ac.uk/en/publications/gefapixant-a-p2x3-receptor-antagonist-for-the-treatment-of-refractory-or-unexplained-chronic-cough-a-randomised-doubleblind-controlled-parallelgroup-phase-2b-trial(5aa94b05-a819-433a-a265-b0ce6c143476).html
Autor:
David Muccino, Jaclyn A. Smith, Alyn H. Morice, Mandel Sher, Lorcan McGarvey, Wen-Chi Wu, Surinder S. Birring
Publikováno v:
Clinical Problems.
Background: We evaluated clinical characteristics of patients with severe refractory/unexplained chronic cough (RCC/UCC). Methods: RCC/UCC subjects (cough duration ≥1 year, severity VAS >40mm) were randomized to placebo or gefapixant (7.5 mg, 20 mg